AI Article Synopsis
- * Although advancements in noninvasive diagnosis methods exist, liver biopsy remains the most reliable way to diagnose NAFLD/NASH, but it depends on the subjective interpretation of pathologists, leading to inconsistencies in results.
- * Artificial intelligence (AI) is emerging as a promising tool to enhance diagnostic accuracy and objectivity in pathology, and several studies—including some by our research group—show its potential in the diagnosis of NAFLD/NASH.
Article Abstract
Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is associated with metabolic syndrome and is rapidly increasing globally with the increased prevalence of obesity. Although noninvasive diagnosis of NAFLD/NASH has progressed, pathological evaluation of liver biopsy specimens remains the gold standard for diagnosing NAFLD/NASH. However, the pathological diagnosis of NAFLD/NASH relies on the subjective judgment of the pathologist, resulting in non-negligible interobserver variations. Artificial intelligence (AI) is an emerging tool in pathology to assist diagnoses with high objectivity and accuracy. An increasing number of studies have reported the usefulness of AI in the pathological diagnosis of NAFLD/NASH, and our group has already used it in animal experiments. In this minireview, we first outline the histopathological characteristics of NAFLD/NASH and the basics of AI. Subsequently, we introduce previous research on AI-based pathological diagnosis of NAFLD/NASH.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113753 | PMC |
| http://dx.doi.org/10.1016/j.csbj.2023.03.048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A significant and persistent rise in the global burden of adolescent NAFLD and NASH estimated by BMI.
Front Public Health
November 2024
Department of Hepatology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Background: Currently, there is a lack of global or even country/regional level data on adolescent non-alcoholic fatty liver disease (NAFLD) prevalence. However, an evidenced dose-dependent relationship exists between body mass index (BMI) and the risk of NAFLD. We aim to estimate the global and regional prevalence of adolescent NAFLD and related non-alcoholic steatohepatitis (NASH) based on BMI.
View Article and Find Full Text PDFLiver magnetic resonance imaging, non-alcoholic fatty liver disease and metabolic syndrome risk in pre-pubertal Mexican boys.
Sci Rep
October 2024
Department of Neuroimaging, King's College London, London, UK.
Rising global pediatric obesity rates, increase non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) prevalence, with MetS being a NAFLD risk factor. NAFLD can be asymptomatic, with liver function tests insensitive to mild disease, and liver biopsy, risking complications. Thus, we investigated multiparametric MRI (mpMRI) metrics of liver fat (proton density fat fraction, PDFF) and disease activity (fibro-inflammation; iron-corrected T1, cT1), in a Hispanic pre-pubertal pediatric cohort, with increased risk of NAFLD.
View Article and Find Full Text PDFPotential impact of ezetimibe on patients with NAFLD/NASH: a meta-analysis of randomized controlled trials.
Front Endocrinol (Lausanne)
October 2024
Department of Endocrinology, Jinzhou Central Hospital, Jinzhou, Liaoning, China.
Article Synopsis
- Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, and ezetimibe has been suggested as a potential supplemental treatment.
- A comprehensive study analyzed the effects of ezetimibe on 578 patients with NAFLD, using data from ten randomized controlled trials.
- Results showed that ezetimibe significantly decreased various liver and cholesterol biomarkers, indicating it may help improve liver function in NAFLD patients.
Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study.
Cardiovasc Diabetol
October 2024
School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Science, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 701, Taiwan.
Background: Non-alcoholic fatty liver diseases (NAFLDs)/non-alcoholic steatohepatitis (NASH) are the most common liver disorders among patients with type 2 diabetes. Newer classes of glucose-lowering agents (GLAs), such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is), have been shown to improve liver-related biomarkers. However, their effects on the development of NAFLD/NASH remain inconclusive.
View Article and Find Full Text PDFPreoperative nonalcoholic steatohepatitis and resolution of metabolic comorbidities after bariatric surgery.
Surg Obes Relat Dis
December 2024
Department of General, Visceral- and Transplantation Surgery, University Hospital Essen, Essen, Germany.
Background: Most patients undergoing bariatric surgery demonstrate elements of the metabolic syndrome (MetS) and can therefore be diagnosed with metabolically unhealthy obesity (MUO). Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) as hepatic manifestations of the MetS occur in many patients with obesity, but their leverage on postoperative improvement to Metabolic Health (MH), defined as absence of any metabolic comorbidity, remains unclear.
Objectives: The aim of this study was to assess the influence of liver health status, operative procedure, and sex on postoperative switch from a MUO to an MH phenotype.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!